Naperville, IL -- (SBWIRE) -- 02/20/2014 -- Reportstack, provider of premium market research reports announces the addition of Ardea Biosciences, Inc. - Strategic SWOT Analysis Review market report to its offering
Ardea Biosciences, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the companys key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy summarization of the companys business strategy.
- SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
Ardea Biosciences, Inc. (Ardea) is a biotechnology company. It focuses on the development of small molecules as novel therapeutics for the treatment of gout and cancer. The companys product portfolio includes three pipeline products, namely, Lesinurad (RDEA 594), RDEA 3170 and Bay 86-9766 (RDEA 119). Lesinurad and RDEA 3170 are currently in Phase-III and Phase-II clinical trials respectively, being developed as a treatment for gout. Bay 86-966 is a Phase-II clinical candidate being developed as a treatment for cancer in a global licensing agreement with Bayer. The company operates as a subsidiary of AstraZeneca PLC. Ardea is headquartered in San Diego, California, the US.
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Ardea Biosciences, Inc.
To view the table of contents for this market research report please visit